Impact Biomedical (IBO) Common Equity (2022 - 2026)
Impact Biomedical's (IBO) quarterly Common Equity came in at $14.7 million in Q1 2026, up 116.02% YoY from $6.8 million in Q1 2025, and up 19.49% on a QoQ basis from $12.3 million in Q4 2025.
Impact Biomedical (IBO) Common Equity (2022 - 2026) Analysis & Trends
Impact Biomedical (IBO) has 5 years of Common Equity data on file, last reported at $14.7 million in Q1 2026.
- Quarterly Common Equity rose 116.02% year-over-year to $14.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.7 million (up 116.02% YoY) and the FY2025 annual result came in at $12.3 million, up 70.11% from the prior year.
- Common Equity climbed to $14.7 million in Q1 2026, from $12.3 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $38.4 million in Q2 2022 to a low of -$8.9 million in Q3 2025.
- A 5-year average of $21.3 million and a median of $27.8 million in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2025 — Common Equity sank 127.97% — and 2026, when it surged 116.02%.
- Tracing IBO's Common Equity over 5 years: stood at $32.7 million in 2022, then dropped by 13.49% to $28.3 million in 2023, then tumbled by 74.39% to $7.2 million in 2024, then surged by 70.11% to $12.3 million in 2025, then increased by 19.49% to $14.7 million in 2026.
- The last three Common Equity figures came in at $14.7 million (Q1 2026), $12.3 million (Q4 2025), and -$8.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Impact Biomedical | 49.54 Mn | 49.53 Mn | 2,000.00 | 14.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.01 Mn |
| Mar 31, 2026 | 14.71 Mn |
| Dec 31, 2025 | 12.31 Mn |
| Sep 30, 2025 | -8.85 Mn |
| Jun 30, 2025 | -7.38 Mn |
| Mar 31, 2025 | 6.81 Mn |
| Dec 31, 2024 | 7.24 Mn |
| Sep 30, 2024 | 34.35 Mn |
| Jun 30, 2024 | 26.38 Mn |
| Mar 31, 2024 | 27.26 Mn |
| Dec 31, 2023 | 28.26 Mn |
| Sep 30, 2023 | 29.58 Mn |
| Jun 30, 2023 | 30.70 Mn |
| Mar 31, 2023 | 31.82 Mn |
| Dec 31, 2022 | 32.67 Mn |
| Sep 30, 2022 | 36.04 Mn |
| Jun 30, 2022 | 38.38 Mn |